Serologic versus molecular testing for screening for hepatitis C virus infection in patients with hematologic malignancies.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
16 Sep 2022
16 Sep 2022
Historique:
entrez:
20
9
2022
pubmed:
21
9
2022
medline:
23
9
2022
Statut:
ppublish
Résumé
Testing for antibody against hepatitis C virus (anti-HCV) is a low-cost diagnostic method worldwide; however, an optimal screening test for HCV in patients with cancer has not been established. We sought to identify an appropriate screening test for HCV infection in patients with hematologic malignancies and/or hematopoietic cell transplants (HCT). Patients in our center were simultaneously screened using serological (anti-HCV) and molecular (HCV RNA) assays (February 2019-November 2019). In total, 214 patients were enrolled in this study. Three patients (1.4%) were positive for anti-HCV, and 2 (0.9%) were positive for HCV RNA. The overall percentage agreement was 99.5% (95% CI: 97.4-99.9). There were no cases of seronegative HCV virus infection. The positive percentage agreement was 66.7% (95% CI: 20.8-93.9), and the negative percentage agreement was 100.0% (95% CI: 98.2-100.0). Cohen kappa coefficient was 0.80 (95% CI: 0.41-1.00, P < .0001). The diagnostic yield of screening for chronic HCV infection in patients with cancer is similar for serologic and molecular testing.
Identifiants
pubmed: 36123927
doi: 10.1097/MD.0000000000030608
pii: 00005792-202209160-00092
pmc: PMC9478288
doi:
Substances chimiques
RNA
63231-63-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30608Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Références
Torres HA, Shigle TL, Hammoudi N, et al. The oncologic burden of hepatitis C virus infection: a clinical perspective. CA Cancer J Clin. 2017;67:411–31.
Torres HA, Pundhir P, Mallet V. Hepatitis C virus infection in patients with cancer: impact on clinical trial enrollment, selection of therapy, and prognosis. Gastroenterology. 2019;157:909–16.
Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74.
WHO Guidelines on Hepatitis B and C Testing. Geneva: World Health Organization, 2017. Available at: https://www.ncbi.nlm.nih.gov/books/NBK442261/table/ch9.t1/ [access January 25, 2022].
Tien PC, Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the veterans affairs hepatitis C resource center program and national hepatitis C program office. Am J Gastroenterol. 2005;100:2338–54.
Macedo de Oliveira A, White KL, Beecham BD, et al. Sensitivity of second-generation enzyme immunoassay for detection of hepatitis C virus infection among oncology patients. J Clin Virol. 2006;35:21–5.
George SL, Gebhardt J, Klinzman D, et al. Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. J Acquir Immune Defic Syndr. 2002;31:154–62.
Torres HA, Chong PP, De Lima M, et al. Hepatitis C virus infection among hematopoietic cell transplant donors and recipients: american society for blood and marrow transplantation task force recommendations. Biol Blood Marrow Transplant. 2015;21:1870–82.
Beld M, Penning M, van Putten M, et al. Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion. Blood. 1999;94:1183–91.
Clifford DB, Smurzynski M, Park LS, et al. Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients. Neurology. 2009;73:309–14.
Kaźmierczak J, Pawełczyk A, Cortes KC, Radkowski M. Seronegative hepatitis C virus infection. Arch Immunol Ther Exp (Warsz). 2014;62:145–51.
Stapleton JT, Klinzman D, Schmidt WN, et al. Prospective comparison of whole-blood- and plasma-based hepatitis C virus RNA detection systems: improved detection using whole blood as the source of viral RNA. J Clin Microbiol. 1999;37:484–9.
Arrojo IP, Pareja MO, Orta MD, et al. Detection of a healthy carrier of HCV with no evidence of antibodies for over four years. Transfusion. 2003;43:953–7.
Wiktor S. How feasible is the global elimination of HCV infection? Lancet. 2019;393:1265–7.
Page K, Osburn W, Evans J, et al. Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection. Clin Infect Dis. 2013;56:405–13.